Scientific research drives innovation at Novartis.
Our researchers work to push the boundaries of science, broaden our understanding of diseases and develop novel products with significant benefits for patients. We are focusing on faulty molecular pathways and therapeutic areas where we see the greatest unmet medical need and believe the scientific tools to address these needs are within reach.
We carry out research at Novartis locations and at partner institutions around the world:
Our offices in Cambridge are located in the midst of multiple renowned academic research institutions and innovative biotech companies. The headquarters is home to research in the areas of oncology, ophthalmology, and cardiovascular and metabolic-related diseases.
Co-located with our corporate world headquarters, our research facility in Basel is an integral part of the BioValley, Europe's biotechnology hub. Drug discovery here focuses on autoimmunity, transplantation, and inflammation, as well as musculoskeletal diseases, neuroscience and oncology
Located on the same campus as our US Pharmaceuticals Division headquarters, our East Hanover location focuses on research in cardiovascular and metabolic diseases. It is also home to information analysis, preclinical safety, and metabolism and pharmacokinetics groups.
Located in the San Francisco Bay area, the Emeryville campus focuses on early discovery and research activities as a hub for infectious disease research, with additional expertise in structural and biophysical chemistry, computer-aided drug design and protein engineering across disease areas.
Novartis has an integrated biomedical Research & Development center in Shanghai’s Zhangjiang Hi-Tech Park in the midst of an emerging cluster of innovative academic, biotech and pharmaceutical research institutions. Research focuses on infectious causes of cancer primarily found in Asia and includes efforts in discovery chemistry and biomarker research.
As a small-molecule drug discovery research institute, NITD combines the drug-discovery expertise and cutting-edge technologies of Novartis to fight infectious tropical diseases.
Founded in 1970, the Friedrich Miescher Institute is devoted to fundamental biomedical research and focuses on epigenetics, growth control and neurobiology.
Located in San Diego’s BioMedical research center, GNF is well-known for developing novel technology to drive cutting-edge drug discovery research, identify new biological pathways and discover mechanisms underlying human disease.